DOP2020000093A - Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en animales - Google Patents

Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en animales

Info

Publication number
DOP2020000093A
DOP2020000093A DO2020000093A DO2020000093A DOP2020000093A DO P2020000093 A DOP2020000093 A DO P2020000093A DO 2020000093 A DO2020000093 A DO 2020000093A DO 2020000093 A DO2020000093 A DO 2020000093A DO P2020000093 A DOP2020000093 A DO P2020000093A
Authority
DO
Dominican Republic
Prior art keywords
animals
treatment
diseases
prevention
fused heteroaromatic
Prior art date
Application number
DO2020000093A
Other languages
English (en)
Inventor
Heisler Iring
Griebenow Nils
Bömer Ulf
Beddies Gerald
De Lourdes Mottier Maria
Cramer Jörg
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of DOP2020000093A publication Critical patent/DOP2020000093A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere al uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y/o la profilaxis de enfermedades alérgicas y/o inflamatorias en los animales y se refiere a su uso para la producción de medicamentos para el tratamiento y/o profilaxis de enfermedades alérgicas y/o inflamatorias en los animales, especialmente de la dermatitis atópica y/o de la dermatitis alérgica por picadura de pulga, y especialmente en animales domésticos, particularmente en los perros.
DO2020000093A 2017-10-19 2020-05-22 Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en animales DOP2020000093A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197344 2017-10-19
PCT/EP2018/078086 WO2019076817A1 (en) 2017-10-19 2018-10-15 USE OF FUSED HETEROAROMATIC PYRROLIDONES FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS

Publications (1)

Publication Number Publication Date
DOP2020000093A true DOP2020000093A (es) 2020-09-30

Family

ID=60143623

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000093A DOP2020000093A (es) 2017-10-19 2020-05-22 Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en animales

Country Status (18)

Country Link
US (1) US11077111B2 (es)
EP (1) EP3665171A1 (es)
JP (1) JP2020537678A (es)
KR (1) KR20200073216A (es)
CN (1) CN111194319A (es)
AU (1) AU2018350683A1 (es)
BR (1) BR112020007679A2 (es)
CA (1) CA3079292A1 (es)
CL (1) CL2020001036A1 (es)
DO (1) DOP2020000093A (es)
IL (1) IL273834A (es)
MX (1) MX2020004155A (es)
PH (1) PH12020550444A1 (es)
RU (1) RU2020116178A (es)
SG (1) SG11202002475TA (es)
TW (1) TW201922744A (es)
UY (1) UY37945A (es)
WO (1) WO2019076817A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237430T3 (es) 1999-06-09 2005-08-01 Yamanouchi Pharmaceutical Co. Ltd. Nuevos derivados carboxamida heterociclicos.
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE396731T1 (de) 2003-03-25 2008-06-15 Vertex Pharma Thiazole zur verwendung als inhibitoren von protein-kinasen
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
AU2007292929A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase
EP3023422A1 (en) 2007-03-12 2016-05-25 YM BioSciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
EA024109B1 (ru) 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
SG2014015085A (en) 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
EP3123864A1 (en) 2008-12-08 2017-02-01 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
CA2782889C (en) 2009-12-17 2014-08-05 Merck Canada Inc. Aminopyrimidines as syk inhibitors
PE20130188A1 (es) 2009-12-23 2013-02-21 Takeda Pharmaceutical Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
WO2012084704A1 (en) 2010-12-20 2012-06-28 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US9056873B2 (en) * 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CR20170249A (es) 2014-12-18 2017-09-25 Takeda Pharmaceuticals Co Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2017207481A1 (en) 2016-06-01 2017-12-07 Bayer Animal Health Gmbh Substituted indazoles ueful for treatment and prevention of allergic and/or inflammatory diseases in animals

Also Published As

Publication number Publication date
MX2020004155A (es) 2020-08-03
UY37945A (es) 2019-05-31
AU2018350683A1 (en) 2020-04-02
RU2020116178A (ru) 2021-11-19
CA3079292A1 (en) 2019-04-25
KR20200073216A (ko) 2020-06-23
SG11202002475TA (en) 2020-04-29
CL2020001036A1 (es) 2020-10-23
WO2019076817A1 (en) 2019-04-25
PH12020550444A1 (en) 2021-04-26
US11077111B2 (en) 2021-08-03
EP3665171A1 (en) 2020-06-17
BR112020007679A2 (pt) 2020-10-20
US20200261461A1 (en) 2020-08-20
JP2020537678A (ja) 2020-12-24
CN111194319A (zh) 2020-05-22
TW201922744A (zh) 2019-06-16
IL273834A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
CL2017003404A1 (es) Compuestos antibacterianos
SV2018005610A (es) Derivados de oxopiridina sustituidos
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
UY36966A (es) Derivados de heterociclos bicíclicos fusionados como plaguicidas
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
CR20150448A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
EA201792006A1 (ru) Антимикробные соединения и способы их получения и их применение
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
CU20200041A7 (es) Amidas de imidazopiridina sustituidas
BR112017013498B8 (pt) Formulação agrícola, seu método de preparação, e composição agrícola aquosa
CR20150479A (es) Composiciones antimicrobianas y métodos de uso relacionados
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
BR112018067922A2 (pt) compostos antibacterianos e seus usos
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
SV2017005444A (es) Método para tratar prevenir o reducir el riesgo de infección cutánea
CO2019002361A2 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
UY36196A (es) Compuestos para usar en el tratamiento antihelmíntico
DOP2020000093A (es) Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en animales
AR113514A1 (es) Composiciones y métodos para mejorar la utilización del fósforo y el calcio en la dieta de los animales
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
DOP2015000290A (es) Benzoxazoles sustituidos